Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

This study provides evidence of a translational exo-metabolomic plasma readout predictive of clinical efficacy together with pharmacodynamic utility following treatment with a signal transduction inhibitor. Mol Cancer Ther; 16(10); 2315–23. ©2017 AACR.

Source: Molecular Cancer Therapeutics - October 2, 2017 Category: Cancer & Oncology Authors: Ang, J. E., Pal, A., Asad, Y. J., Henley, A. T., Valenti, M., Box, G., de haven Brandon, A., Revell, V. L., Skene, D. J., Venturi, M., Rueger, R., Meresse, V., Eccles, S. A., de Bono, J. S., Kaye, S. B., Workman, P., Banerji, U., Raynaud, F. I. Tags: Companion Diagnostics and Cancer Biomarkers Source Type: research